Details of Disease

General Information of Disease (ID: DIS1V20Y)

• Disease Name: Differentiated thyroid carcinoma
• Synonyms: well-differentiated thyroid cancer; papillary or follicular thyroid carcinoma; thyroid gland differentiated carcinoma; thyroid gland well differentiated carcinoma; differentiated thyroid carcinoma; well-differentiated thyroid carcinoma; well differentiated thyroid carcinoma; differentiated thyroid gland carcinoma; differentiated thyroid cancer; differentiated thyroid gland cancer; well differentiated thyroid gland carcinoma
• Definition: Differentiated thyroid carcinoma (DTC), also known as papillary or follicular thyroid carcinoma, is a slow-growing malignancy usually presenting in adults as an asymptomatic thyroid mass.
• Disease Hierarchy:
  DISMNGZ0: Thyroid gland carcinoma
  DIS1V20Y: Differentiated thyroid carcinoma
• Disease Identifiers:
  MONDO ID: MONDO_0015447
  UMLS CUI: C1337013
  MedGen ID: 277876
  Orphanet ID: 146
  SNOMED CT ID: 1255086008

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 11 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
FOLH1	TT9G4N0	Limited	Biomarker	[1]
TPO	TT52XDZ	Limited	Genetic Variation	[2]
CYP24A1	TT82UI1	moderate	Altered Expression	[3]
DEPTOR	TTLYP6D	Strong	Altered Expression	[4]
GRK5	TTTCXO0	Strong	Altered Expression	[5]
LGR4	TTY6C71	Strong	Biomarker	[6]
NRG1	TTEH395	Strong	Genetic Variation	[7]
PIGU	TT2LHI6	Strong	Biomarker	[8]
SLC8B1	TTJN46R	Strong	Biomarker	[7]
TKTL1	TTNQ1J3	Strong	Altered Expression	[9]
TPCN1	TTODQE2	Strong	Biomarker	[10]

This Disease Is Related to 7 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP27B1	DE3FYEM	moderate	Altered Expression	[3]
CYP2R1	DEBIHM3	Strong	Genetic Variation	[11]
UGT1A10	DEL5N6Y	Strong	Genetic Variation	[12]
UGT1A3	DEF2WXN	Strong	Biomarker	[13]
UGT1A4	DELOY3P	Strong	Genetic Variation	[12]
UGT1A6	DESD26P	Strong	Genetic Variation	[12]
UGT1A8	DE2GB8N	Strong	Genetic Variation	[12]

This Disease Is Related to 32 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
NKX2-1	OTCMEJTA	Limited	Biomarker	[7]
PTTG1IP	OTX21QTE	Limited	Genetic Variation	[14]
GTF2I	OTUYL1TQ	moderate	Biomarker	[15]
GTF2IRD1	OTEG9KU1	moderate	Biomarker	[15]
AMFR	OTQRX7LC	Strong	Altered Expression	[16]
CEP78	OTTAI5S2	Strong	Altered Expression	[17]
CNTN5	OTWU5FLZ	Strong	Biomarker	[18]
CNTN6	OTXVGVOR	Strong	Biomarker	[18]
DIO2	OTGPNSLH	Strong	Genetic Variation	[13]
HOPX	OTBSR6C9	Strong	Posttranslational Modification	[19]
NEIL3	OTBCI2NS	Strong	Genetic Variation	[20]
PATZ1	OT0X9WGR	Strong	Biomarker	[21]
PJA2	OT45TMC4	Strong	Altered Expression	[22]
RAD23B	OT0PGOG3	Strong	Genetic Variation	[23]
RAD52	OT0OTDHI	Strong	Genetic Variation	[24]
RAP1GAP	OTC31ONQ	Strong	Altered Expression	[25]
RFC3	OT1MS7AO	Strong	Genetic Variation	[20]
RPA1	OT76POLP	Strong	Genetic Variation	[20]
SEPTIN11	OTX2O0ZX	Strong	Biomarker	[7]
SLURP1	OT89YD2E	Strong	Biomarker	[26]
SNX5	OT6ZOWMU	Strong	Altered Expression	[27]
SPATA13	OTQ8NPAW	Strong	Genetic Variation	[28]
SPINT1	OT1CLR5L	Strong	Altered Expression	[29]
TCEAL4	OTX24CQI	Strong	Altered Expression	[30]
TSC22D3	OT03UM03	Strong	Altered Expression	[31]
FOXE1	OT5IR5IT	Definitive	Genetic Variation	[32]
GDF1	OTZ1VRBH	Definitive	Biomarker	[33]
PCNX2	OT90S9W6	Definitive	Genetic Variation	[7]
PPP1R13L	OTNCPLWE	Definitive	Biomarker	[33]
RNH1	OT6EC79B	Definitive	Biomarker	[33]
SHC3	OT305NPA	Definitive	Biomarker	[33]
SMUG1	OT2YIOCQ	Definitive	Biomarker	[34]

References

• [1] Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.J Nucl Med. 2019 Sep;60(Suppl 2):13S-19S. doi: 10.2967/jnumed.118.220566.
• [2] TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations.Int J Cancer. 2013 Dec 15;133(12):2843-51. doi: 10.1002/ijc.28317. Epub 2013 Jul 13.
• [3] Altered expression of key players in vitamin D metabolism and signaling in malignant and benign thyroid tumors.J Histochem Cytochem. 2012 Jul;60(7):502-11. doi: 10.1369/0022155412447296. Epub 2012 Apr 17.
• [4] Overexpression of DEP domain containing mTOR-interacting protein correlates with poor prognosis in differentiated thyroid carcinoma.Mol Med Rep. 2011 Sep-Oct;4(5):817-23. doi: 10.3892/mmr.2011.503. Epub 2011 Jun 2.
• [5] Expression and activity of g protein-coupled receptor kinases in differentiated thyroid carcinoma.J Clin Endocrinol Metab. 2002 Jul;87(7):3279-86. doi: 10.1210/jcem.87.7.8618.
• [6] Upregulation of RSPO2-GPR48/LGR4 signaling in papillary thyroid carcinoma contributes to tumor progression.Oncotarget. 2017 Nov 25;8(70):114980-114994. doi: 10.18632/oncotarget.22692. eCollection 2017 Dec 29.
• [7] Genome-wide association and expression quantitative trait loci studies identify multiple susceptibility loci for thyroid cancer.Nat Commun. 2017 Jul 13;8:15966. doi: 10.1038/ncomms15966.
• [8] Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx092.
• [9] Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines.Invest New Drugs. 2009 Aug;27(4):297-303. doi: 10.1007/s10637-008-9174-8. Epub 2008 Sep 20.
• [10] The Chinese herb Prunella vulgaris promotes apoptosis in human well-differentiated thyroid carcinoma cells via the B-cell lymphoma-2/Bcl-2-associated X protein/caspase-3 signaling pathway.Oncol Lett. 2017 Aug;14(2):1309-1314. doi: 10.3892/ol.2017.6317. Epub 2017 Jun 6.
• [11] Impaired vitamin D activation and association with CYP24A1 haplotypes in differentiated thyroid carcinoma.Thyroid. 2012 Jul;22(7):709-16. doi: 10.1089/thy.2011.0330. Epub 2012 Jun 12.
• [12] Association of the UGT1A1-53(TA)n polymorphism with L-thyroxine doses required for thyrotropin suppression in patients with differentiated thyroid cancer.Pharmacogenet Genomics. 2011 Jun;21(6):341-3. doi: 10.1097/FPC.0b013e3283448d19.
• [13] Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer.Br J Clin Pharmacol. 2014 Nov;78(5):1067-75. doi: 10.1111/bcp.12437.
• [14] The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells.Endocrinology. 2014 Apr;155(4):1222-34. doi: 10.1210/en.2013-1646. Epub 2014 Feb 7.
• [15] Technetium-99m-pertechnetate whole-body SPET/CT scan in thyroidectomized differentiated thyroid cancer patients is a useful imaging modality in detecting remnant thyroid tissue, nodal and distant metastases before (131)I therapy. A study of 416 patients.Hell J Nucl Med. 2018 May-Aug;21(2):121-124.
• [16] Expression of Gp78/Autocrine Motility Factor Receptor and Endocytosis of Autocrine Motility Factor in Human Thyroid Cancer Cells.Cureus. 2019 Jun 17;11(6):e4928. doi: 10.7759/cureus.4928.
• [17] Significance of CEP78 and WDR62 gene expressions in differentiated thyroid carcinoma: Possible predictors of lateral lymph node metastasis.Asia Pac J Clin Oncol. 2019 Oct;15(5):e154-e161. doi: 10.1111/ajco.13143. Epub 2019 Mar 18.
• [18] The influence of neural cell adhesion molecule isoform 140 on the metastasis of thyroid carcinoma.Clin Exp Metastasis. 2013 Mar;30(3):299-307. doi: 10.1007/s10585-012-9537-6. Epub 2012 Sep 27.
• [19] HOPX homeobox methylation in differentiated thyroid cancer and its clinical relevance.Endocr Connect. 2018 Dec;7(12):1333-1342. doi: 10.1530/EC-18-0380.
• [20] Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma.DNA Repair (Amst). 2016 May;41:27-31. doi: 10.1016/j.dnarep.2016.03.011. Epub 2016 Mar 31.
• [21] PATZ1 knockdown enhances malignant phenotype in thyroid epithelial follicular cells and thyroid cancer cells.Oncotarget. 2017 Aug 2;8(47):82754-82772. doi: 10.18632/oncotarget.19787. eCollection 2017 Oct 10.
• [22] Expression of the ring ligase PRAJA2 in thyroid cancer.J Clin Endocrinol Metab. 2012 Nov;97(11):4253-9. doi: 10.1210/jc.2012-2360. Epub 2012 Sep 4.
• [23] The role of CCNH Val270Ala (rs2230641) and other nucleotide excision repair polymorphisms in individual susceptibility to well-differentiated thyroid cancer.Oncol Rep. 2013 Nov;30(5):2458-66. doi: 10.3892/or.2013.2702. Epub 2013 Aug 27.
• [24] Increased risk of differentiated thyroid carcinoma with combined effects of homologous recombination repair gene polymorphisms in an Iranian population.Asian Pac J Cancer Prev. 2014 Jan;14(11):6727-31. doi: 10.7314/apjcp.2013.14.11.6727.
• [25] Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells.Endocr Relat Cancer. 2011 Apr 2;18(3):301-10. doi: 10.1530/ERC-10-0320. Print 2011 Jun.
• [26] Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma.Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):190-195. doi: 10.1007/s00259-016-3485-3. Epub 2016 Aug 16.
• [27] Loss of sorting nexin 5 stabilizes internalized growth factor receptors to promote thyroid cancer progression.J Pathol. 2017 Nov;243(3):342-353. doi: 10.1002/path.4951.
• [28] Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk.J Clin Endocrinol Metab. 2014 Oct;99(10):E2084-92. doi: 10.1210/jc.2014-1734. Epub 2014 Jul 16.
• [29] Expression of serine peptidase inhibitor Kunitz type 1 in differentiated thyroid cancer.Histochem Cell Biol. 2018 Jun;149(6):635-644. doi: 10.1007/s00418-018-1660-2. Epub 2018 Mar 12.
• [30] Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.BMC Cancer. 2006 Nov 1;6:260. doi: 10.1186/1471-2407-6-260.
• [31] Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.Cell Death Dis. 2018 Feb 21;9(3):305. doi: 10.1038/s41419-018-0346-y.
• [32] Exploration of the association between FOXE1 gene polymorphism and differentiated thyroid cancer: a meta-analysis.BMC Med Genet. 2018 May 22;19(1):83. doi: 10.1186/s12881-018-0604-y.
• [33] LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND BONE METASTASES.Endocr Pract. 2019 May;25(5):427-437. doi: 10.4158/EP-2018-0465. Epub 2019 Jan 18.
• [34] Role of (18)F-Choline Positron Emission Tomography/Computed Tomography to Detect Structural Relapse in High-Risk Differentiated Thyroid Cancer Patients.Thyroid. 2019 Apr;29(4):549-556. doi: 10.1089/thy.2018.0552.